These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35393455)

  • 21. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.
    Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF
    J Psychoactive Drugs; 2023; 55(1):73-84. PubMed ID: 35001856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
    Simonsson O; Goldberg SB
    J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.
    Yaden DB; Berghella AP; Regier PS; Garcia-Romeu A; Johnson MW; Hendricks PS
    Int J Drug Policy; 2021 Dec; 98():103380. PubMed ID: 34329952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in the Top-Cited Articles on Classic Psychedelics.
    Lawrence DW; Sharma B; Griffiths RR; Carhart-Harris R
    J Psychoactive Drugs; 2021; 53(4):283-298. PubMed ID: 33535907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
    Jones GM; Nock MK
    Sci Rep; 2022 Oct; 12(1):16976. PubMed ID: 36216840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classic Psychedelics and Human-Animal Relations.
    Pöllänen E; Osika W; Stenfors CUD; Simonsson O
    Int J Environ Res Public Health; 2022 Jul; 19(13):. PubMed ID: 35805769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and associations of classic psychedelic-related seizures in a population-based sample.
    Simonsson O; Goldberg SB; Chambers R; Osika W; Long DM; Hendricks PS
    Drug Alcohol Depend; 2022 Oct; 239():109586. PubMed ID: 35981469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlates of specialty substance use treatment among adults with opioid use disorders.
    Romo E; Ulbricht CM; Clark RE; Lapane KL
    Addict Behav; 2018 Nov; 86():96-103. PubMed ID: 29551551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal associations between age 20 problematic substance use and opioid use disorder incidence at age 30 - findings from an urban cohort.
    Thrul J; Rabinowitz JA; Reboussin BA; Maher BS; Anthony JC; Ialongo NS
    J Psychiatr Res; 2023 Apr; 160():1-7. PubMed ID: 36764195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
    Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
    Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
    Carhart-Harris RL; Goodwin GM
    Neuropsychopharmacology; 2017 Oct; 42(11):2105-2113. PubMed ID: 28443617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.
    Garcia-Romeu A; Davis AK; Erowid E; Erowid F; Griffiths RR; Johnson MW
    Front Psychiatry; 2019; 10():955. PubMed ID: 32038317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.
    Nayak SM; Gukasyan N; Barrett FS; Erowid E; Erowid F; Griffiths RR
    Pharmacopsychiatry; 2021 Sep; 54(5):240-245. PubMed ID: 34348413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
    Sexton JD; Nichols CD; Hendricks PS
    Front Psychiatry; 2019; 10():896. PubMed ID: 32116806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.